
    
      This study is comprised of two cohorts as below:

      Cohort A: inoperable, untreated, non-small cell lung cancer patients

      Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents
      including immune checkpoint inhibitors
    
  